# Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

> **NCT07714070** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Endometrial Cancer
- Atypical Endometrial Hyperplasia
- Progestin Resistance

## Interventions

- **DRUG:** Orlistat
- **DRUG:** Progestin

## Key facts

- **NCT ID:** NCT07714070
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-09
- **Final completion:** 2029-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714070, "Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07714070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*